RxDoctor Payments Data

Rebecca Beyer

Nurse Practitioner · Stuart, FLNPI 1528585304

Payments from drug & device makers

$9,700in general payments, 2019–2025

Across 429 payments — averaging $22.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Actelion Pharmaceuticals US, Inc.$1K
  • United Therapeutics Corporation$678
  • GSK$625
  • Inogen, Inc.$570
  • Boehringer Ingelheim$514
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$9,700100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,700 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$13,089
Medicare patients
110
Services billed
169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide37$37,937
OzempicSemaglutide34$37,444
JanuviaSitagliptin Phosphate23$30,690
EliquisApixaban20$20,649
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$20,254
RybelsusSemaglutide18$17,574
XareltoRivaroxaban18$15,373
TradjentaLinagliptin15$12,233
SynthroidLevothyroxine Sodium90$7,996
Rosuvastatin Calcium310$5,409
Breo ElliptaFluticasone/Vilanterol11$4,352
Levothyroxine Sodium250$2,499
Losartan Potassium174$2,028
Atorvastatin Calcium183$1,713
Albuterol Sulfate HfaAlbuterol Sulfate43$1,708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$223$55,01952 claims
Lilly USA, LLCMounjaro$138$37,93737 claims
MerckJanuvia$182$30,69023 claims
GSKTrelegy Ellipta, Breo Ellipta$625$24,60641 claims
PfizerEliquis$463$20,64920 claims
Johnson & JohnsonXarelto$36$15,37318 claims
Boehringer IngelheimTradjenta$514$12,23315 claims
AbbVieSynthroid$115$7,99690 claims
ANI Pharmaceuticals, Inc.Valsartan$33$83230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Stuart

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →